Xing Shen - Lotus Pharmaceuticals VP of Corporate Devel.

LTUS Stock  USD 0.01  0  25.00%   

VP

Dr. Xing Shen, Ph.D., is Vice President Corporationrationrate Development of Lotus Pharmaceuticals, Inc. He was with the Company since July 2009. From July 2006 through May 2009, Mr. Shen was an associate equity analyst for RBC Capital Markets, where he cocovered approximately 30 companies in the biotech industry. Mr. Shen received a Masters of Business Administration in 2006 and a Doctorate in Molecular Cancer Biology in 2000 from Duke University. Mr. Shen received a MS in plant molecular biology from Peking University in 1995 and a BS in Virology from Wuhan University in 1992 since 2010.
Age 52
Tenure 14 years
Professional MarksCFA
Phone615 310 2688
Webhttps://lotuspharmaceuticalsusa.com
Shen has received Series 7, 63, 86 and 87 licenses from Finra and is a Chartered Financial Analyst level one candidate.

Lotus Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.0456 % which means that it generated a profit of $0.0456 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0182 %, meaning that it created $0.0182 on every $100 dollars invested by stockholders. Lotus Pharmaceuticals' management efficiency ratios could be used to measure how well Lotus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 5.24 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Lotus Pharmaceuticals has a current ratio of 0.52, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Lotus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Lotus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Lotus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Lotus to invest in growth at high rates of return. When we think about Lotus Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the Peoples Republic of China. Lotus Pharmaceutical operates under Shell Companies classification in the United States and is traded on OTC Exchange. It employs 233 people. Lotus Pharmaceuticals [LTUS] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Lotus Pharmaceuticals Leadership Team

Elected by the shareholders, the Lotus Pharmaceuticals' board of directors comprises two types of representatives: Lotus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lotus. The board's role is to monitor Lotus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Lotus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lotus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Li Zhaohui, Independent Director
Fan Lijun, Independent Director
Xing Shen, VP of Corporate Devel.
Yan Zeng, CFO and Principal Accounting Officer
Lu Jun, Director
Zhongyi Liu, Chairman of the Board and Presidentident, CEO
Zhong Liu, Chairman, Founder

Lotus Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Lotus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lotus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for Lotus Pink Sheet analysis

When running Lotus Pharmaceuticals' price analysis, check to measure Lotus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lotus Pharmaceuticals is operating at the current time. Most of Lotus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lotus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lotus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lotus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Please note, there is a significant difference between Lotus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lotus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lotus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.